GLAXO

March 31 (Reuters) - GlaxoSmithKline Pharmaceuticals Ltd GLAX.NS:

• GLAXOSMITHKLINE PHARMACEUTICALS LTD - RECEIVES TDS DEMAND LIABILITY OF 20.1 MILLION RUPEES

Source text: ID:nBSEbNrKqt

Further company coverage: GLAX.NS

((Reuters.Briefs@thomsonreuters.com;))

March 24 (Reuters) - GlaxoSmithKline Pharmaceuticals Ltd GLAX.NS:

• GLAXOSMITHKLINE PHARMACEUTICALS LTD - RECEIVES FINAL ORDER WITH TAX DEMAND LIABILITY OF 232.1 MILLION RUPEES FOR AY 2023-2024

Source text: ID:nBSE7RqnSk

Further company coverage: GLAX.NS

((Reuters.Briefs@thomsonreuters.com;))

March 16 (Reuters) - GlaxoSmithKline Pharmaceuticals Ltd GLAX.NS:

• GLAXOSMITHKLINE PHARMACEUTICALS LTD - JUBY CHANDY RESIGNS AS WHOLE-TIME DIRECTOR AND CFO

Source text: ID:nBSE84bnN1

Further company coverage: GLAX.NS

((Reuters.Briefs@thomsonreuters.com;))

March 2 (Reuters) - GlaxoSmithKline Pharmaceuticals Ltd GLAX.NS:

• RONOJIT BISWAS APPOINTED AS WHOLE-TIME DIRECTOR & CFO

• JUBY CHANDY TO STEP DOWN AS WHOLE-TIME DIRECTOR & CFO

Source text: ID:nBSE1LMSK6

Further company coverage: GLAX.NS

((Reuters.Briefs@thomsonreuters.com;))

Feb 23 (Reuters) - GlaxoSmithKline Pharmaceuticals Ltd GLAX.NS:

• GETS ORDER WITH TOTAL TAX DEMAND OF 37.9 MILLION RUPEES INCLUDING TAX, PENALTY

Source text: ID:nBSE3gzSbb

Further company coverage: GLAX.NS

((Reuters.Briefs@thomsonreuters.com;))

Feb 9 (Reuters) - GlaxoSmithKline Pharmaceuticals Ltd GLAX.NS:

• GLAXOSMITHKLINE PHARMACEUTICALS LTD - DEC-QUARTER CONSOL PROFIT 2.96 BILLION RUPEES

• GLAXOSMITHKLINE PHARMACEUTICALS LTD - DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 10.41 BILLION RUPEES

Source: https://nsearchives.nseindia.com/corporate/GLAXO1924_09022026152039_OutcomeofBoardMeeting.pdf

Further company coverage: GLAX.NS

((Reuters.Briefs@thomsonreuters.com;))

Dec 31 (Reuters) - GlaxoSmithKline Pharmaceuticals Ltd GLAX.NS:

• GETS TAX DEMAND OF 85.7 MILLION RUPEES

Source text: ID:nBSEdyxQX

Further company coverage: GLAX.NS

((Reuters.Briefs@thomsonreuters.com;;))

** GlaxoSmithKline Pharmaceuticals GLAX.NS rises as much as 2.5% to 2,869 rupees; set to gain for second straight session

** Pharma co forays into oncology in India, with Jemperli and Zejula to treat gynaecological cancers

** More than 70,000 shares traded, below 30-day moving avg of 104,281

** GLAX last up ~1%, taking YTD gains to 24.3%

(Reporting by Meenakshi Maidas in Bengaluru)

((meenakshi.maidas@thomsonreuters.com;))

Aug 1 (Reuters) - Indian drugmaker GlaxoSmithKline Pharma GLAX.NS reported its first quarterly revenue decline in more than two years on Friday, leading to its shares declining the most in nearly four months.

The Indian unit of British drugmaker GSK Plc GSK.L reported a 2% decline in its revenue from operations to 8.05 billion rupees ($92 million)for the first quarter ended June 30.

GlaxoSmithKline Pharma said its performance during the quarter was "below anticipated levels," as it was hurt by "external factors such as seasonal disruptions".

The stock slumped 5.5% after results and was on track for its worst day since early April.

This is the company's first revenue drop since March 2023, when it grappled with lower prices of its key drugs due to the government's pricing cap.

Separately, in May, it had a temporary production disruption due to a fire at one of its contract manufacturing facilities, but did not disclose whether there was a financial impact from it.

Its quarterly profit climbed 12.5% on-year to 2.05 billion rupees as the company kept a tight lid on its expenses. Total expenses for the quarter dropped 5.2%.

($1 = 87.4090 Indian rupees)

(Reporting by Kashish Tandon in Bengaluru; Editing by Janane Venkatraman)

((Kashish.Tandon@thomsonreuters.com; 8800437922;))

June 19 (Reuters) - GlaxoSmithKline Pharmaceuticals Ltd GLAX.NS:

• RECEIVES TOTAL TAX DEMAND ORDER OF 30.7 MILLION RUPEES

Source text: ID:nBSE8hWFp3

Further company coverage: GLAX.NS

((Reuters.Briefs@thomsonreuters.com;;))

April 11 (Reuters) - GlaxoSmithKline Pharmaceuticals Ltd GLAX.NS:

• GETS TAX ORDER OF 216.3 MILLION RUPEES

Source text: [ID:]

Further company coverage: GLAX.NS

((Reuters.Briefs@thomsonreuters.com;;))

** Shares of GlaxoSmithKline Pharmaceuticals GLAX.NS jump 12.4% to 2,266 rupees

** Drugmaker reports 35% Y/Y jump in third-quarter adjusted profit, rev up 18% Y/Y

** GLAX's profit growth driven by strong demand for its respiratory drugs and antibiotic Augmentin, while demand for its vaccines also boosted earnings

** Analysts' avg rating on GLAX at "buy"; median PT is 2,675.50 rupees - data compiled by LSEG

** Stock gained 19% in 2024

(Reporting by Kashish Tandon in Bengaluru)

((Kashish.tandon@thomsonreuters.com))

Feb 14 (Reuters) - GlaxoSmithKline Pharmaceuticals Ltd GLAX.NS:

• GLAXOSMITHKLINE PHARMA Q3 CONSOL PROFIT 2.3 BILLION RUPEES

• GLAXOSMITHKLINE PHARMA Q3 CONSOL REVENUE FROM OPERATIONS 9.49 BILLION RUPEES

• GLAXOSMITHKLINE PHARMACEUTICALS - RE-APPOINTMENT OF JUBY CHANDY AS CHIEF FINANCIAL OFFICER

Source text: ID:nBSE1JhsBH

Further company coverage: GLAX.NS

((Reuters.Briefs@thomsonreuters.com;;))

Feb 5 (Reuters) - GlaxoSmithKline Pharmaceuticals Ltd GLAX.NS:

• GLAXOSMITHKLINE PHARMACEUTICALS - GOT TAX DEMAND ORDER OF 4.8 MILLION RUPEES

Source text: ID:nBSE836t2c

Further company coverage: GLAX.NS

((reuters.briefs@thomsonreuters.com;))

** Shares of GlaxoSmithKline Pharma GLAX.NS rise 2% to 2,682 rupees

** The pharma co posted a 15% uptick in Q2 consol profit before tax to 3.44 bln rupees (~$41 mln)

** Rev for ops grew 5.6%, driven by strong demand for its generic drugs and vaccines

** Stock up 41% so far this year

($1 = 84.0770 Indian rupees)

(Reporting by Ashna Teresa Britto in Bengaluru)

((AshnaTeresa.Britto@thomsonreuters.com ; ( +91 8078332441))

Oct 29 (Reuters) - GlaxoSmithKline Pharmaceuticals Ltd GLAX.NS:

• SEPT-QUARTER PROFIT 2.53 BILLION RUPEES

• SEPT-QUARTER REVENUE FROM OPERATIONS 10.11 BILLION RUPEES

• NUMBERS ARE IN CONSOLIDATED BASIS

• DIVIDEND 12 RUPEES PER SHARE

Source text: ID:nBSE4pH2MH

Further company coverage: GLAX.NS

((Reutersbriefs@thomsonreuters.com;))

Adds details and background in paragraphs 3-7, responses from Moderna and GSK in paragraph 3

By Blake Brittain

Oct 15 (Reuters) - British drugmaker GlaxoSmithKline GLAX.NS sued Moderna MRNA.O in U.S. federal court in Delaware on Tuesday, accusing its American rival of violating GSK's patent rights in messenger RNA (mRNA) technology with its blockbuster COVID-19 vaccine Spikevax.

According to the two lawsuits, Moderna's lipid nanoparticles for transporting fragile mRNA into the human body infringe several GSK patents covering similar innovations. GSK filed a related lawsuit against Pfizer PFE.N and BioNTech 22UAy.DE in the same court in April over their COVID-19 vaccine. The new litigation seeks unspecified monetary damages.

A Moderna spokesperson said the company was aware of the new litigation and would defend itself against the claims. A GSK spokesperson said the drugmaker is "willing to license these patents on commercially reasonable terms and to ensure continued patient access."

The lawsuits add to a web of U.S. court cases involving Pfizer, BioNTech and Moderna over patent royalties for technology used in their vaccines, including one brought by Moderna against Pfizer in 2022.

Moderna earned $6.7 billion in revenue from Spikevax last year. Pfizer made $11.2 billion from sales of its and BioNTech's vaccine Comirnaty. Sales of both vaccines declined significantly last year from 2022.

GSK said in the new litigation that its patents cover mRNA technology pioneered in 2008 that provides "the foundation for Moderna's mRNA vaccine portfolio." GSK said it bought the rights to the inventions when it acquired part of Novartis' NOVN.S vaccine business in 2015.

(Reporting by Blake Brittain
Editing by David Bario and Will Dunham)

((blake.brittain@thomsonreuters.com;))

Sept 3 (Reuters) - GlaxoSmithKline Pharmaceuticals Ltd GLAX.NS:

• GETS INCOME TAX REFUND ORDER FOR 2.22 BILLION RUPEES

Source text for Eikon: ID:nNSE6ckYJW

Further company coverage: GLAX.NS

(Reporting by VijayDattaram Malkar)

((VijayDattaram.Malkar@thomsonreuters.com;))

Aug 30 (Reuters) - GlaxoSmithKline Pharmaceuticals Ltd GLAX.NS:

• GLAXOSMITHKLINE PHARMACEUTICALS - GETS TAX ORDER OF 21 MILLION RUPEES, INTEREST 15 MILLION RUPEES

Further company coverage: GLAX.NS

((reuters.briefs@thomsonreuters.com;))

Aug 26 (Reuters) - GlaxoSmithKline Pharmaceuticals Ltd GLAX.NS:

• GLAXOSMITHKLINE PHARMA- ORDER FROM PUNJAB GST AUTHORITIES DROPPING PROCEEDINGS OF SHOW CAUSE NOTICE

Source text for Eikon: ID:nBSE3xk4Wb

Further company coverage: GLAX.NS

((Reuters.Briefs@thomsonreuters.com;))

Aug 8 (Reuters) - GlaxoSmithKline Pharmaceuticals Ltd GLAX.NS:

• GLAXOSMITHKLINE PHARMACEUTICALS - GOT TAX DEMAND AGGREGATING TO 9.8 MILLION RUPEES

Source text for Eikon: ID:nBSE6gW1mq

Further company coverage: GLAX.NS

((Reuters.Briefs@thomsonreuters.com;))

June 25 (Reuters) - GlaxoSmithKline Pharmaceuticals Ltd GLAX.NS:

• GOT ORDER FROM GST OFFICE RAISING DEMAND OF 716.6 MILLION RUPEES

Further company coverage: GLAX.NS

((Reuters.Briefs@thomsonreuters.com;))

BENGALURU, May 17 (Reuters) - Drugmaker GlaxoSmithKline Pharma India GLAX.NS reported a 49% rise in fourth-quarter adjusted profit on Friday, as strong demand for its generic medicines offset the impact of the government's ongoing price curbs on its key drugs.

The company reported consolidated profit before exceptional items and taxes of 2.68 billion rupees ($32.1 million) for the quarter ended March 31, compared to 1.80 billion rupees a year earlier.

In the year-ago period, the Indian unit of UK's GSK GSK.L had an exceptional charge of 104 million rupees which comprised restructuring and other costs.

The company's shares closed up 13.7% after the results.

Revenue from operations rose 18% to 9.30 billion rupees, led by a 12% growth in its generic medicines portfolio which the company attributed to key focus brands Augmentin, Ceftum and Calpol.

Earnings at drugmakers like GlaxoSmithKline Pharma and Abbott India ABOT.NS have been pressured as prices of some of their key drugs were capped under the Indian government's essential medicines list (NLEM) since September 2022.

However, "despite the NLEM impact in previous quarters, all promoted brands outpaced their respective categories in growth and gained market share," the company said in a statement.

Last week, rival Abbott India reported a higher fourth-quarter profit, led by strong sales.

($1 = 83.3825 Indian rupees)

(Reporting by Kashish Tandon in Bengaluru; Editing by Varun H K)

((Kashish.Tandon@thomsonreuters.com; 8800437922;))

BENGALURU, May 9 (Reuters) - Indian drugmaker Abbott India ABOT.NS reported a 24% rise in fourth-quarter profit on Thursday, as strong sales outpaced the impact of government pricing caps on certain medicines.

The company, which makes the popular antacid medicine Digene, said its profit rose to 2.87 billion rupees ($34.3 million) for the three months ended March 31, from 2.31 billion rupees a year earlier.

Revenues of drugmakers such as Abbott India and GlaxoSmithKline Pharma India GLAX.NS, which get most of their business from India, have been impacted after the inclusion of some of their drugs in the government's essential medicines list in September 2022, making them susceptible to price caps.

Abbott, which is a unit of U.S. healthcare firm Abbott Laboratories ABT.N, has been trying to mitigate the impact of pricing curbs by driving up sales and cutting back on expenses.

The company, which makes drugs including hypothyroidism treatment tablets Thyronorm, said its revenue from operations rose 7% to 14.39 billion rupees in the fourth quarter.

The company declared a dividend of 410 rupees per share for fiscal year 2024.

($1 = 83.4760 Indian rupees)

(Reporting by Kashish Tandon in Bengaluru; Editing by Mrigank Dhaniwala)

((Kashish.Tandon@thomsonreuters.com; 8800437922;))

Adds response from BioNTech in paragraph 3

By Blake Brittain

April 25 (Reuters) - GlaxoSmithKline GLAX.NS sued Pfizer PFE.N and BioNTech 22UAy.DE in Delaware federal court on Thursday, accusing them of infringing GSK patents related to messenger RNA (mRNA) technology in the companies' blockbuster COVID-19 vaccines.

GSK said in the lawsuit that Pfizer and BioNTech's Comirnaty vaccines violate the company's patent rights in mRNA-vaccine innovations developed "more than a decade before" the outbreak of the COVID-19 pandemic.

A Pfizer spokesperson said in a statement that the company is "confident in our IP position around Comirnaty" and intends to "vigorously defend" against GSK's claims. A BioNTech spokesperson declined to comment on the complaint.

A GSK spokesperson said the company believes its patents "provided the foundational technology used in Pfizer and BioNTech’s COVID-19 mRNA vaccines," and that it is "willing to license these patents on commercially reasonable terms and to ensure continued patient access" to the shots.

The lawsuit adds to a web of high-stakes U.S. court cases involving Pfizer, BioNTech and Moderna over patent royalties for technology used in their vaccines, including a case brought by Moderna against Pfizer in 2022.

Pfizer made $11.2 billion from sales of Comirnaty last year, while Moderna earned $6.7 billion in revenue from its vaccine Spikevax. Sales of both vaccines declined significantly last year from 2022.

London-based GSK asked the court for an unspecified amount of monetary damages from Pfizer and BioNTech that includes an ongoing patent-licensing fee.

GSK said in the complaint that its patents cover technology for transporting fragile mRNA into human cells that scientists began developing in 2008. GSK said it bought the rights to the inventions when it acquired part of Novartis' NOVN.S vaccines business in 2015.

GSK also sued Pfizer for patent infringement last year over technology used in Pfizer's respiratory syncytial virus (RSV) vaccine Abrysvo. Pfizer has denied GSK's claims in that case.

(Reporting by Blake Brittain
Editing by David Bario and Chizu Nomiyama and Franklin Paul)

((blake.brittain@thomsonreuters.com))

BENGALURU, Feb 12 (Reuters) - GlaxoSmithKline Pharmaceuticals GLAX.NS, the Indian unit of the UK's GSK GSK.L, reported a 3% fall in third-quarter profit on Monday, hurt by the government's pricing cap on certain medicines.

Consolidated profit before exceptional items and tax for the quarter ended Dec. 31 was 2.29 billion rupees ($27.6 million), compared with 2.36 billion rupees a year earlier.

GlaxoSmithKline, which derives most of its revenue from India, continued to grapple with challenges following the inclusion of its key products such as Ceftum antibiotic and T-Bact ointment in the country's National List of Essential Medicines (NLEM) in September 2022, mandating sales below a government-set price ceiling.

It's revenue declined for three straight quarters following the adoption of the list before rebounding on the growth in its vaccine business in the June quarter of last fiscal year.

Revenue from operations rose a meagre 0.4% to 8.05 billion rupees in the latest quarter.

The company, which makes Augmentin antibiotic, incurred a one-time charge of 1.63 billion rupees, related to the cost of a voluntary retirement scheme and other employee dues.

It also had a one-time charge of 113.7 million rupees in the year-ago period, due to restructuring costs.

Last month, parent GSK beat market estimates for its fourth-quarter results and provided an upbeat forecast for 2024 and beyond, citing the expansion of its vaccines and cancer drugs pipeline.

Earlier this month, rival Abbott India ABOT.NS reported a 26% jump in third-quarter profit on elevated sales.

($1 = 82.9720 Indian rupees)

(Reporting by Kashish Tandon in Bengaluru; Editing by Dhanya Ann Thoppil)

((Kashish.Tandon@thomsonreuters.com;))

Feb 1 (Reuters) - GlaxoSmithKline Pharmaceuticals Ltd GLAX.NS:

• GOT ORDER FROM INCOME TAX DEPARTMENT WITH INCOME TAX LIABILITY OF 168.4 MILLION RUPEES

Source text for Eikon: ID:nBSE2QvTqk

Further company coverage: GLAX.NS

((Reuters.Briefs@thomsonreuters.com;;))

** Shares of GlaxoSmithKline Pharmaceuticals GLAX.NS rise as much as 8.3% to a record 2,259 rupees; last up 4.9%

** Reuters could not immediately verify the reason for the move

** Stock last hit all-time highs in December while logging gains for 11 straight sessions

** Stock has risen about 5% twice so far in January and had risen about 5% thrice throughout 2023

** Avg analyst rating on GLAX stock is "hold", same as rival Dr Reddy's REDY.NS; Sun Pharma SUN.NS, Cipla's CIPL.NS avg rating is "buy" - LSEG data

** GLAX's avg PT is 1,686.5 rupees, 23% lower than current price - LSEG data

(Reporting by Varun Vyas in Bengaluru)

((varunvyas.hebbalalu@thomsonreuters.com))

GlaxoSmithKline Pharmaceuticals Ltd GLAX.NS:

• GLAXOSMITHKLINE PHARMACEUTICALS LTD- GOT ORDER FOR GST DEMAND AT 10.7 MILLION RUPEES

Source text for Eikon: ID:nBSE4jZJMb

Further company coverage: GLAX.NS